Saturday, October 31, 2026

MicroStrategy Stock Bullish Momentum With A 9% Jump As Session Comes To An End Today

ViaNews Editorial Team

February 15, 2023

MicroStrategy Stock Bullish Momentum With A 9% Jump As Session Comes To An End Today

(VIANEWS) - Shares of MicroStrategy (NASDAQ: MSTR) jumped 9.78% to $297.65 at 15:46 EST on Wednesday, after two successive sessions in a row of gains. NASDAQ is jumping 0.65% to $12,038.03, after two successive sessions in a row of gains. This seems, as yet, a somewhat positive trend exchanging session today.

MicroStrategy's last close was $271.14, 48.14% under its 52-week high of $522.80.

About MicroStrategy

MicroStrategy Incorporated provides enterprise analytics software and services worldwide. It offers MicroStrategy, an enterprise platform, which provides a modern analytics experience by delivering insights across multiple devices to users via hyperintelligence products, visualization and reporting capabilities, mobility features, and custom applications developed on the platform; analysts and data scientists with seamless access to trusted, governed data directly within their tools; and APIs and gateways, multiple deployment options, enterprise semantic graph, scalability, and security. The company also provides MicroStrategy Support that helps customers to achieve their system availability and uptime goals, and to improve the overall experience through highly responsive troubleshooting and proactive technical product support. In addition, it offers MicroStrategy Consulting that provides customers with architecture and implementation services to help them quickly realize results, and helps to achieve returns on investment derived from understanding of data; and MicroStrategy Education that offers free and paid learning options. The company provides its services through enterprise sales force and channel partners. It serves companies from a range of industries, including retail, consulting, technology, manufacturing, finance, banking, insurance, healthcare, education, and telecommunications, as well as the public sector. The company was incorporated in 1989 and is headquartered in Tysons Corner, Virginia.

Earnings Per Share

As for profitability, MicroStrategy has a trailing twelve months EPS of $-12.31.

Volume

Today's last reported volume for MicroStrategy is 558036 which is 3.24% below its average volume of 576750.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MicroStrategy's stock is considered to be oversold (<=20).

Volatility

MicroStrategy's last week, last month's, and last quarter's current intraday variation average was a negative 0.49%, a positive 1.11%, and a positive 4.24%.

MicroStrategy's highest amplitude of average volatility was 6.09% (last week), 4.28% (last month), and 4.24% (last quarter).

Moving Average

MicroStrategy's worth is way higher than its 50-day moving average of $208.28 and way above its 200-day moving average of $228.24.

More news about MicroStrategy (MSTR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com